Evidence map›Paper›PMID 42420197›Full record

ArticlemAbs2026

Predicting antibody self-association with sequence-structure fusion models: the central role of CSI-BLI in early developability screening.

Shafayat Ahmed, Federico Devalle, Lauren Leisen, Tony Pham, Bismark Amofah, Amber Lee, Mark Hutchinson, Chacko Chakiath, Jen DiChiara, Sharfa Farzandh and 6 more

Abstract read
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shafayat AhmedData Science and Modelling, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Federico DevalleData Science and Modelling, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Lauren LeisenData Science and Modelling, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Tony PhamBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Bismark AmofahBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Amber LeeBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0002-7793-1669
Mark HutchinsonBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Chacko ChakiathBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Jen DiChiaraBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Sharfa FarzandhBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Madi KreitzDosage Form Design and Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Alison HintonDosage Form Design and Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Neil ModyDosage Form Design and Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Andrew DippelBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0003-3453-0803
Gilad KaplanBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0003-1374-305X
Maryam PouryahyaData Science and Modelling, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-based biologics are expanding rapidly, yet challenges in development from self-association, high viscosity, aggregation, and unfavorable clearance underscore the need for accurate in silico screening. Clone self-interaction biolayer interferometry (CSI-BLI) is a plate-based, low-material assay of weak, reversible self-association that serves as an early proxy for high-concentration viscosity and a complementary predictor of in vivo clearance. In a panel of 246 monoclonal antibodies, CSI-BLI moderately correlates with viscosity; further, in hFcRn Tg32 mice (41 antibodies), CSI-BLI strongly associates with clearance. Here, we present an end-to-end framework that distinguishes high versus low self-interacting clones (CSI-BLI class) by coupling a fine-tuned protein language model (ESM-2) with residue-aligned 3D context from AlphaFold-predicted structures encoded as residue graphs. Disentangled multi-stream attention fuses sequence content, chain-aware positional information, and structural signals to capture spatially proximate interactions that are distant in sequence. Edit-distance - controlled splits across 1499 IgGs and 841 VHHs assess generalization. The structure-aware model achieves the highest hold-out performance (VHH F1 = 0.76; IgG F1 = 0.57), while a sequence-only disentangled variant outperforms a standard protein language model baseline without structural inputs. Complementary biophysical feature-based models, built from AlphaFold structures and sequence/structure-derived physicochemical descriptors with cluster-aware selection, deliver robust, interpretable performance (VHH; F1 = 0.72; IgG F1 = 0.57), with Shapley value analyses highlighting charge/dipole, hydrophobicity, and aggregation-propensity drivers across complementarity-determining regions and Frameworks. This interaction-aware sequence-structure framework, supported by interpretable feature models, is extensible to other developability endpoints and broader protein classification tasks where joint modeling of language-derived representations and residue-level geometry is advantageous.

Indexed as

Antibodies, MonoclonalAnimalsHumansInterferometryMiceModels, MolecularAntibodies, MonoclonalCSI BLIFine-tuningGNNPLM

Identifiers

PMID42420197
PMCPMC13349016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.